Latest News Archive

Please select Category, Year, and then Month to display items

UFS campuses inclusive and accessible

17 March 2021 | Story University Estates | Photo UFS Photo Archive

wheelchair ramp_web read more — The UFS is committed to providing inclusive and accessible living, teaching, and learning spaces that are welcoming to all.

In accordance with its vision to be a university that is recognised across the world for excellence in academic achievement and human reconciliation, the University of the Free State (UFS) is committed to providing a universally accessible environment for all students, staff, and visitors on all three of its campuses.

A sense of belonging and togetherness

Creating an accessible environment that is conducive and welcoming to everybody on the campuses – which were not designed with accessibility in mind – is not an easy task. When the principles of universal design and access are applied, the environment and spaces can be enjoyed by all users alike, creating a sense of belonging and togetherness. The common perception that accessibility only provides equitable access and opportunities for persons in wheelchairs is refuted by universal access, stating that it is to the advantage and for the use of everybody. Parents with infants in strollers, delivery persons with trolleys or carrying heavy material, library patrons carrying an armful of books, academic staff with wheeled (rolling) laptop bags, and older people all benefit from the availability of a ramp, elevator, or automated door.

The current accessibility project of the UFS was initiated in 2009, evaluating the accessibility status of the UFS at the time. Priority inaccessible areas and spaces were identified and listed to be converted and improved over a period of five years, revising the list every year. The focus of the project was primarily on areas and spaces where most student activities take place, where specific needs and challenges have been identified, and where specific departments/divisions of the UFS have requested the improvement of access. The project does not only include access to buildings, but also accessible bathrooms, sufficient accessible parking spaces, accessible walkways, and accessibility within the classroom. The emphasis of the project is not only on wheelchair users and persons with mobility impairments, but also on creating an environment that can easily be navigated and used by everybody.

All new infrastructure incorporates accessibility measures

University Estates updated the accessibility reports mid-2020 and identified project priorities up to 2024. Among other things, the key focus areas were to make all walkways wheelchair-friendly, to create ablution facilities for persons with disabilities, to install lifts in buildings, and to install ramps. All new infrastructure by default incorporates accessibility measures in the planning stage.

On the South Campus, ramps were installed around the campus and pathways were made wheelchair-friendly. Entrances to existing lecture halls and other buildings have also been made more user-friendly for persons with disabilities. Additional to the above-mentioned initiatives, the institution has also embarked on a project that seeks to assist the visually impaired to better navigate the campus.

For our Qwaqwa Campus, immediate critical interventions that are in the planning stage and that should be done within the next year, are the creation of accessible ablution facilities in the Administration Building, library, and the Humanities and Education buildings.

WATCH video below:

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept